期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

凋亡抑制因子Livin在膀胱癌中表达的意义 被引量：1

原文传递
导出
摘要 凋亡抑制因子Livin是新近发现的一个IAP(inhibitor of apoptosis protein)家族成员,其可以抑制细胞凋亡,在肿瘤的发病机制中起着重要作用。近年来,关于Livin与膀胱癌发生、发展的关系,及其与肿瘤分期、分级、复发相关性的大小的研究已经成为热点。将Livin用作肿瘤标记物并实现其作为新靶点的基因治疗,将为膀胱癌诊断和治疗提供一种新的有效的方法。本文对此作一综述。
作者 杨飞亚 王建文 邢念增
机构地区 首都医科大学附属北京朝阳医院泌尿外科
出处 《临床泌尿外科杂志》 北大核心 2009年第10期788-790,共3页 Journal of Clinical Urology
关键词 膀胱癌 凋亡抑制因子 基因治疗
分类号 R737.14 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Ozen H, Hall M C. Bladder cancer[J]. Curr Opin On- col, 2000, 12:255-259.
  • 2Hassen W, Droller M J. Current concepts in assessment and treatment of bladder cancer[J]. Curr Opin Urol, 2000, 10:291--299.
  • 3Stein J P, Grossfeld G D, Ginsberg D A, et al. Prognostic marker in bladder cancer:a contemporary review of the literature[J]. J Urol, 1998,160 : 645-- 659.
  • 4Salvesen G S, Duckett C S. IAP proteins: Blocking the road to death,s door[J]. Nat RevMol Cell Biol, 2002, 3(6) :401--410.
  • 5Kosof G M, Gomes B C. Livin,a novel inhibitor of apoptosis protein family member[J]. J Biol Chem, 2001, 276(5) :3238--3246.
  • 6Ashhab Y, Alian A, Polliack A, et al. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pat tern[J]. FEBS Lett, 2001, 495(12) :56--60.
  • 7LinJ H, Deng G, Huang Q, etal. KIAP, a novel member of the inhibitor of apoptosis protein family[J]. Biochem BiophysRes Comm un, 2000, 279(3):820--831.
  • 8Vucic D, Stennicke H R, Pisabarro M T, et al. ML-IAP, a novel inhibitor Of apoptosis that is preferentially expressed in human melanomas[J]. Curr Biol, 2000,10 (21):1359--1366.
  • 9Vucic D, Franklin M C, Wallweber H J, et al. Engineering ML-IAP to produce an extraordinarily potent easpase 9 inhibitor:implications for smae dependent antiap-optotic activity of ML-IAP[J]. Biochem J, 2005, 385(ptl) :11--20.
  • 10Sanna M G, da Silva Correia J, Ducrey O, et al. lAP suppression o- apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition[J]. Mol Cell Biol, 2002,22 (6): 1754 -- 1766.

二级参考文献7

  • 1Kasof G M, Gomes B C. Livin, a novel inhibitor of apoptosis protein family member[J]. J Biol Chem, 2001,276: 3238-3246.
  • 2Germana Sanna M, Jean da Silva Correia, Odile Ducrey,et al. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition[J]. Mol Cell Biol, 2002, 22(6) :1754-1766.
  • 3Ashhab Y, Alian A, Plliack A, et al. Two splicing variants of apoptosis gene with different biological properties and tissue distribution pattern[J]. FEBS Lett,2001, 495:56-60.
  • 4Gazzaniga P, Gradilone A, Giuliani L. Expression and prognostic significance of Livin,Survivin and other apoptosis-related genes in the progression of superficial bladder cancer[J]. Annal of Oneology, 2003, 14 : 85-90.
  • 5Jan C. Schmollinger, Robert H. Vonderheide, et al.Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction [J].PNAS, 2003, 100(6): 3398-3403.
  • 6Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the Iivin/ML-IAP/KIAP gene[J]. Oncogene, 2003, 22(51): 8330-8336.
  • 7Vucic D, Deshayes K, Ackerly H, et al. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP)[J]. J Biol Chem,2002, 277(14): 12275-12279.

共引文献30

同被引文献10

  • 1Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer[J]. Onco Targets and Therapy, 2011, 4:97-113.
  • 2Tauszig DS, Bouzas RJ. Targeting neurotrophin-3 and its depen- dence receptor tyrosine kinase receptor C: a new antitumoral strategy[J]. Expert Opin Ther Targets, 2011, 15(7): 847-858.
  • 3Parkin MD, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002[J]. CA Cancer J Clin, 2005, 55:74-108.
  • 4Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder[J]. J Urol, 2002, 167(4):1573-1583.
  • 5Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer[J]. N Engl J Med, 1990, 322 (16):1129-1138.
  • 6Thress K, Macintyre T, Wang H, et M. Identification and pre- clinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway[J]. Mol Cancer Ther, 2009, 8(7):1818-27.
  • 7Akil H, Perraud A, M 6 lin C, et al. Fine-Tuning Roles of Endogenous Brain-Derived Neurotrophic Factor, TrkB and Sortilin in Colorectal Cancer Cell Survival[J]. PLoS One, 2011, 6(9):e25097.
  • 8Prakash Y, Thompson MA, Meuchel L, et al. Nettrotrophins in lung health and disease[J]. Expert Rev Respir Meal, 2010, 4(3):395-411.
  • 9Sosman JA, Puzanov I, Atkins MB. Opportunities and obsta- cles to combination targeted therapy in renal cell cancer[J]. Clin Cancer Res, 2007, 13(2 Pt 2):764-769.
  • 10in W, Yun C, Jeong J, et al. c-Src is required for tropomyo- sin receptor kinase C (TrkC)-induced activation of the phos- phatidylinositol 3-kinase (PI3K)-AKT pathway[J]. J Biol Chem, 2008, 283(3):1391-1400.

引证文献1

二级引证文献3

临床泌尿外科杂志
2009年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部